KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
AcquisitionsAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesOther financing activitiesShare-based CompensationShort-Term Debt issuances
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Boston Scientific (BSX) Long-Term Debt Repayments (2016 - 2020)

Boston Scientific (BSX) has disclosed Long-Term Debt Repayments for 11 consecutive years, with $1.4 billion as the latest value for Q2 2020.

  • Quarterly Long-Term Debt Repayments changed N/A to $1.4 billion in Q2 2020 from the year-ago period, while the trailing twelve-month figure was $1.4 billion through Mar 2021, up 200.63% year-over-year, with the annual reading at $1.9 billion for FY2020, N/A changed from the prior year.
  • Long-Term Debt Repayments hit $1.4 billion in Q2 2020 for Boston Scientific, up from $479.0 million in the prior quarter.
  • In the past five years, Long-Term Debt Repayments ranged from a high of $1.4 billion in Q2 2020 to a low of -$33.0 million in Q2 2018.
  • Historically, Long-Term Debt Repayments has averaged $339.8 million across 4 years, with a median of $250.0 million in 2017.
  • Biggest five-year swings in Long-Term Debt Repayments: soared 775.0% in 2017 and later plummeted 109.43% in 2018.
  • Year by year, Long-Term Debt Repayments stood at $210.0 million in 2016, then skyrocketed by 90.48% to $400.0 million in 2017, then tumbled by 108.25% to -$33.0 million in 2018, then skyrocketed by 4463.64% to $1.4 billion in 2020.
  • Business Quant data shows Long-Term Debt Repayments for BSX at $1.4 billion in Q2 2020, $479.0 million in Q1 2020, and -$33.0 million in Q4 2018.